Last reviewed · How we verify
RUBOXISTAURIN
RUBOXISTAURIN works by blocking a specific enzyme called Protein Kinase C theta type, which is involved in inflammation and fibrosis.
RUBOXISTAURIN is a small molecule drug that targets Protein Kinase C theta type. It is classified as a ruboxistaurin, but its commercial status and approved indications are unknown. The mechanism of action involves inhibiting Protein Kinase C theta type, which plays a role in inflammation and fibrosis. As a result, RUBOXISTAURIN may be used to treat conditions associated with these processes. However, its development and approval status are unclear.
At a glance
| Generic name | RUBOXISTAURIN |
|---|---|
| Drug class | ruboxistaurin |
| Target | Citron Rho-interacting kinase, Homeodomain-interacting protein kinase 1, Homeodomain-interacting protein kinase 3 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Mechanism of action
Think of Protein Kinase C theta type like a messenger that helps cells talk to each other. When this messenger gets out of control, it can lead to inflammation and scarring. RUBOXISTAURIN acts like a brake, slowing down this messenger to prevent excessive inflammation and fibrosis.
Approved indications
Common side effects
Key clinical trials
- Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos (PHASE2)
- Ruboxistaurin in New York Heart Failure Classification III-IV Patients (PHASE1,PHASE2)
- The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes (PHASE2)
- Reduction in the Occurrence of Center-Involved Diabetic Macular Edema (PHASE3)
- Effect of Ruboxistaurin on Clinically Significant Macular Edema (PHASE3)
- Treatment for Completers of the Study B7A-MC-MBCM (PHASE3)
- Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study (PHASE3)
- Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RUBOXISTAURIN CI brief — competitive landscape report
- RUBOXISTAURIN updates RSS · CI watch RSS